Open1.260 | Close1.650 |
Vol / Avg.3.094M / 246.588K | Mkt Cap41.927M |
Day Range1.250 - 1.700 | 52 Wk Range1.235 - 10.200 |
Leap Therapeutics Stock (NASDAQ: LPTX) stock price, news, charts, stock research, profile.
Open1.260 | Close1.650 |
Vol / Avg.3.094M / 246.588K | Mkt Cap41.927M |
Day Range1.250 - 1.700 | 52 Wk Range1.235 - 10.200 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.900 | -0.910 | -0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-15 | Baird | Joel Beatty | Maintains | OutperformOutperform | Lowers | 30.00 | 20.00 |
2023-08-15 | HC Wainwright & Co. | Swayampakula Ramakanth | Maintains | BuyBuy | Raises | 2.50 | 7.00 |
2023-07-13 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Raises | 17.00 | 18.50 |
2023-06-23 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Lowers | 20.00 | 17.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
LPTX | Leap Therapeutics | 26.15% | 41.9M |
CRIS | Curis | -1.35% | 30.2M |
COEP | Coeptis Therapeutics | 0% | 33.5M |
PHXM | PHAXIAM Therapeutics | -6.4% | 28.9M |
ALGS | Aligos Therapeutics | -4.01% | 33.4M |
You can purchase shares of Leap Therapeutics (NASDAQ: LPTX) through any online brokerage.
Other companies in Leap Therapeutics’s space includes: Curis (NASDAQ:CRIS), Coeptis Therapeutics (NASDAQ:COEP), PHAXIAM Therapeutics (NASDAQ:PHXM), Aligos Therapeutics (NASDAQ:ALGS) and NuCana (NASDAQ:NCNA).
The latest price target for Leap Therapeutics (NASDAQ: LPTX) was reported by Baird on Tuesday, August 15, 2023. The analyst firm set a price target for 20.00 expecting LPTX to rise to within 12 months (a possible 1119.51% upside). 12 analyst firms have reported ratings in the last year.
The stock price for Leap Therapeutics (NASDAQ: LPTX) is $1.64 last updated October 3, 2023 at 11:40 PM UTC.
There is no dividend information for Leap Therapeutics.
Leap Therapeutics’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Leap Therapeutics.
Leap Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Leap Therapeutics Stock (NASDAQ: LPTX) stock price, news, charts, stock research, profile.
Open1.260 | Close1.650 |
Vol / Avg.3.094M / 246.588K | Mkt Cap41.927M |
Day Range1.250 - 1.700 | 52 Wk Range1.235 - 10.200 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.900 | -0.910 | -0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-15 | Baird | Joel Beatty | Maintains | OutperformOutperform | Lowers | 30.00 | 20.00 |
2023-08-15 | HC Wainwright & Co. | Swayampakula Ramakanth | Maintains | BuyBuy | Raises | 2.50 | 7.00 |
2023-07-13 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Raises | 17.00 | 18.50 |
2023-06-23 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Lowers | 20.00 | 17.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
LPTX | Leap Therapeutics | 26.15% | 41.9M |
CRIS | Curis | -1.35% | 30.2M |
COEP | Coeptis Therapeutics | 0% | 33.5M |
PHXM | PHAXIAM Therapeutics | -6.4% | 28.9M |
ALGS | Aligos Therapeutics | -4.01% | 33.4M |
You can purchase shares of Leap Therapeutics (NASDAQ: LPTX) through any online brokerage.
Other companies in Leap Therapeutics’s space includes: Curis (NASDAQ:CRIS), Coeptis Therapeutics (NASDAQ:COEP), PHAXIAM Therapeutics (NASDAQ:PHXM), Aligos Therapeutics (NASDAQ:ALGS) and NuCana (NASDAQ:NCNA).
The latest price target for Leap Therapeutics (NASDAQ: LPTX) was reported by Baird on Tuesday, August 15, 2023. The analyst firm set a price target for 20.00 expecting LPTX to rise to within 12 months (a possible 1119.51% upside). 12 analyst firms have reported ratings in the last year.
The stock price for Leap Therapeutics (NASDAQ: LPTX) is $1.64 last updated October 3, 2023 at 11:40 PM UTC.
There is no dividend information for Leap Therapeutics.
Leap Therapeutics’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Leap Therapeutics.
Leap Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Leap Therapeutics Stock (NASDAQ: LPTX) stock price, news, charts, stock research, profile.
Open1.260 | Close1.650 |
Vol / Avg.3.094M / 246.588K | Mkt Cap41.927M |
Day Range1.250 - 1.700 | 52 Wk Range1.235 - 10.200 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.900 | -0.910 | -0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-15 | Baird | Joel Beatty | Maintains | OutperformOutperform | Lowers | 30.00 | 20.00 |
2023-08-15 | HC Wainwright & Co. | Swayampakula Ramakanth | Maintains | BuyBuy | Raises | 2.50 | 7.00 |
2023-07-13 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Raises | 17.00 | 18.50 |
2023-06-23 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Lowers | 20.00 | 17.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
LPTX | Leap Therapeutics | 26.15% | 41.9M |
CRIS | Curis | -1.35% | 30.2M |
COEP | Coeptis Therapeutics | 0% | 33.5M |
PHXM | PHAXIAM Therapeutics | -6.4% | 28.9M |
ALGS | Aligos Therapeutics | -4.01% | 33.4M |
You can purchase shares of Leap Therapeutics (NASDAQ: LPTX) through any online brokerage.
Other companies in Leap Therapeutics’s space includes: Curis (NASDAQ:CRIS), Coeptis Therapeutics (NASDAQ:COEP), PHAXIAM Therapeutics (NASDAQ:PHXM), Aligos Therapeutics (NASDAQ:ALGS) and NuCana (NASDAQ:NCNA).
The latest price target for Leap Therapeutics (NASDAQ: LPTX) was reported by Baird on Tuesday, August 15, 2023. The analyst firm set a price target for 20.00 expecting LPTX to rise to within 12 months (a possible 1119.51% upside). 12 analyst firms have reported ratings in the last year.
The stock price for Leap Therapeutics (NASDAQ: LPTX) is $1.64 last updated October 3, 2023 at 11:40 PM UTC.
There is no dividend information for Leap Therapeutics.
Leap Therapeutics’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Leap Therapeutics.
Leap Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Leap Therapeutics Stock (NASDAQ: LPTX) stock price, news, charts, stock research, profile.
Open1.260 | Close1.650 |
Vol / Avg.3.094M / 246.588K | Mkt Cap41.927M |
Day Range1.250 - 1.700 | 52 Wk Range1.235 - 10.200 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.900 | -0.910 | -0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-15 | Baird | Joel Beatty | Maintains | OutperformOutperform | Lowers | 30.00 | 20.00 |
2023-08-15 | HC Wainwright & Co. | Swayampakula Ramakanth | Maintains | BuyBuy | Raises | 2.50 | 7.00 |
2023-07-13 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Raises | 17.00 | 18.50 |
2023-06-23 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Lowers | 20.00 | 17.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
LPTX | Leap Therapeutics | 26.15% | 41.9M |
CRIS | Curis | -1.35% | 30.2M |
COEP | Coeptis Therapeutics | 0% | 33.5M |
PHXM | PHAXIAM Therapeutics | -6.4% | 28.9M |
ALGS | Aligos Therapeutics | -4.01% | 33.4M |
You can purchase shares of Leap Therapeutics (NASDAQ: LPTX) through any online brokerage.
Other companies in Leap Therapeutics’s space includes: Curis (NASDAQ:CRIS), Coeptis Therapeutics (NASDAQ:COEP), PHAXIAM Therapeutics (NASDAQ:PHXM), Aligos Therapeutics (NASDAQ:ALGS) and NuCana (NASDAQ:NCNA).
The latest price target for Leap Therapeutics (NASDAQ: LPTX) was reported by Baird on Tuesday, August 15, 2023. The analyst firm set a price target for 20.00 expecting LPTX to rise to within 12 months (a possible 1119.51% upside). 12 analyst firms have reported ratings in the last year.
The stock price for Leap Therapeutics (NASDAQ: LPTX) is $1.64 last updated October 3, 2023 at 11:40 PM UTC.
There is no dividend information for Leap Therapeutics.
Leap Therapeutics’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Leap Therapeutics.
Leap Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Leap Therapeutics Stock (NASDAQ: LPTX) stock price, news, charts, stock research, profile.
Open1.260 | Close1.650 |
Vol / Avg.3.094M / 246.588K | Mkt Cap41.927M |
Day Range1.250 - 1.700 | 52 Wk Range1.235 - 10.200 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.900 | -0.910 | -0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-15 | Baird | Joel Beatty | Maintains | OutperformOutperform | Lowers | 30.00 | 20.00 |
2023-08-15 | HC Wainwright & Co. | Swayampakula Ramakanth | Maintains | BuyBuy | Raises | 2.50 | 7.00 |
2023-07-13 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Raises | 17.00 | 18.50 |
2023-06-23 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Lowers | 20.00 | 17.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
LPTX | Leap Therapeutics | 26.15% | 41.9M |
CRIS | Curis | -1.35% | 30.2M |
COEP | Coeptis Therapeutics | 0% | 33.5M |
PHXM | PHAXIAM Therapeutics | -6.4% | 28.9M |
ALGS | Aligos Therapeutics | -4.01% | 33.4M |
You can purchase shares of Leap Therapeutics (NASDAQ: LPTX) through any online brokerage.
Other companies in Leap Therapeutics’s space includes: Curis (NASDAQ:CRIS), Coeptis Therapeutics (NASDAQ:COEP), PHAXIAM Therapeutics (NASDAQ:PHXM), Aligos Therapeutics (NASDAQ:ALGS) and NuCana (NASDAQ:NCNA).
The latest price target for Leap Therapeutics (NASDAQ: LPTX) was reported by Baird on Tuesday, August 15, 2023. The analyst firm set a price target for 20.00 expecting LPTX to rise to within 12 months (a possible 1119.51% upside). 12 analyst firms have reported ratings in the last year.
The stock price for Leap Therapeutics (NASDAQ: LPTX) is $1.64 last updated October 3, 2023 at 11:40 PM UTC.
There is no dividend information for Leap Therapeutics.
Leap Therapeutics’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Leap Therapeutics.
Leap Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Leap Therapeutics Stock (NASDAQ: LPTX) stock price, news, charts, stock research, profile.
Open1.260 | Close1.650 |
Vol / Avg.3.094M / 246.588K | Mkt Cap41.927M |
Day Range1.250 - 1.700 | 52 Wk Range1.235 - 10.200 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.900 | -0.910 | -0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-15 | Baird | Joel Beatty | Maintains | OutperformOutperform | Lowers | 30.00 | 20.00 |
2023-08-15 | HC Wainwright & Co. | Swayampakula Ramakanth | Maintains | BuyBuy | Raises | 2.50 | 7.00 |
2023-07-13 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Raises | 17.00 | 18.50 |
2023-06-23 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Lowers | 20.00 | 17.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
LPTX | Leap Therapeutics | 26.15% | 41.9M |
CRIS | Curis | -1.35% | 30.2M |
COEP | Coeptis Therapeutics | 0% | 33.5M |
PHXM | PHAXIAM Therapeutics | -6.4% | 28.9M |
ALGS | Aligos Therapeutics | -4.01% | 33.4M |
You can purchase shares of Leap Therapeutics (NASDAQ: LPTX) through any online brokerage.
Other companies in Leap Therapeutics’s space includes: Curis (NASDAQ:CRIS), Coeptis Therapeutics (NASDAQ:COEP), PHAXIAM Therapeutics (NASDAQ:PHXM), Aligos Therapeutics (NASDAQ:ALGS) and NuCana (NASDAQ:NCNA).
The latest price target for Leap Therapeutics (NASDAQ: LPTX) was reported by Baird on Tuesday, August 15, 2023. The analyst firm set a price target for 20.00 expecting LPTX to rise to within 12 months (a possible 1119.51% upside). 12 analyst firms have reported ratings in the last year.
The stock price for Leap Therapeutics (NASDAQ: LPTX) is $1.64 last updated October 3, 2023 at 11:40 PM UTC.
There is no dividend information for Leap Therapeutics.
Leap Therapeutics’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Leap Therapeutics.
Leap Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Leap Therapeutics Stock (NASDAQ: LPTX) stock price, news, charts, stock research, profile.
Open1.260 | Close1.650 |
Vol / Avg.3.094M / 246.588K | Mkt Cap41.927M |
Day Range1.250 - 1.700 | 52 Wk Range1.235 - 10.200 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.900 | -0.910 | -0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-15 | Baird | Joel Beatty | Maintains | OutperformOutperform | Lowers | 30.00 | 20.00 |
2023-08-15 | HC Wainwright & Co. | Swayampakula Ramakanth | Maintains | BuyBuy | Raises | 2.50 | 7.00 |
2023-07-13 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Raises | 17.00 | 18.50 |
2023-06-23 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Lowers | 20.00 | 17.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
LPTX | Leap Therapeutics | 26.15% | 41.9M |
CRIS | Curis | -1.35% | 30.2M |
COEP | Coeptis Therapeutics | 0% | 33.5M |
PHXM | PHAXIAM Therapeutics | -6.4% | 28.9M |
ALGS | Aligos Therapeutics | -4.01% | 33.4M |
You can purchase shares of Leap Therapeutics (NASDAQ: LPTX) through any online brokerage.
Other companies in Leap Therapeutics’s space includes: Curis (NASDAQ:CRIS), Coeptis Therapeutics (NASDAQ:COEP), PHAXIAM Therapeutics (NASDAQ:PHXM), Aligos Therapeutics (NASDAQ:ALGS) and NuCana (NASDAQ:NCNA).
The latest price target for Leap Therapeutics (NASDAQ: LPTX) was reported by Baird on Tuesday, August 15, 2023. The analyst firm set a price target for 20.00 expecting LPTX to rise to within 12 months (a possible 1119.51% upside). 12 analyst firms have reported ratings in the last year.
The stock price for Leap Therapeutics (NASDAQ: LPTX) is $1.64 last updated October 3, 2023 at 11:40 PM UTC.
There is no dividend information for Leap Therapeutics.
Leap Therapeutics’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Leap Therapeutics.
Leap Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Leap Therapeutics Stock (NASDAQ: LPTX) stock price, news, charts, stock research, profile.
Open1.260 | Close1.650 |
Vol / Avg.3.094M / 246.588K | Mkt Cap41.927M |
Day Range1.250 - 1.700 | 52 Wk Range1.235 - 10.200 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.900 | -0.910 | -0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-15 | Baird | Joel Beatty | Maintains | OutperformOutperform | Lowers | 30.00 | 20.00 |
2023-08-15 | HC Wainwright & Co. | Swayampakula Ramakanth | Maintains | BuyBuy | Raises | 2.50 | 7.00 |
2023-07-13 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Raises | 17.00 | 18.50 |
2023-06-23 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Lowers | 20.00 | 17.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
LPTX | Leap Therapeutics | 26.15% | 41.9M |
CRIS | Curis | -1.35% | 30.2M |
COEP | Coeptis Therapeutics | 0% | 33.5M |
PHXM | PHAXIAM Therapeutics | -6.4% | 28.9M |
ALGS | Aligos Therapeutics | -4.01% | 33.4M |
You can purchase shares of Leap Therapeutics (NASDAQ: LPTX) through any online brokerage.
Other companies in Leap Therapeutics’s space includes: Curis (NASDAQ:CRIS), Coeptis Therapeutics (NASDAQ:COEP), PHAXIAM Therapeutics (NASDAQ:PHXM), Aligos Therapeutics (NASDAQ:ALGS) and NuCana (NASDAQ:NCNA).
The latest price target for Leap Therapeutics (NASDAQ: LPTX) was reported by Baird on Tuesday, August 15, 2023. The analyst firm set a price target for 20.00 expecting LPTX to rise to within 12 months (a possible 1119.51% upside). 12 analyst firms have reported ratings in the last year.
The stock price for Leap Therapeutics (NASDAQ: LPTX) is $1.64 last updated October 3, 2023 at 11:40 PM UTC.
There is no dividend information for Leap Therapeutics.
Leap Therapeutics’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Leap Therapeutics.
Leap Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Leap Therapeutics Stock (NASDAQ: LPTX) stock price, news, charts, stock research, profile.
Open1.260 | Close1.650 |
Vol / Avg.3.094M / 246.588K | Mkt Cap41.927M |
Day Range1.250 - 1.700 | 52 Wk Range1.235 - 10.200 |
Q3 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED) | ||||||
REV |
Q2 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.900 | -0.910 | -0.0100 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|---|---|---|---|---|---|---|
2023-08-15 | Baird | Joel Beatty | Maintains | OutperformOutperform | Lowers | 30.00 | 20.00 |
2023-08-15 | HC Wainwright & Co. | Swayampakula Ramakanth | Maintains | BuyBuy | Raises | 2.50 | 7.00 |
2023-07-13 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Raises | 17.00 | 18.50 |
2023-06-23 | Raymond James | Steven Seedhouse | Maintains | OutperformOutperform | Lowers | 20.00 | 17.00 |
Ticker | Company | Chg % | Mkt Cap |
---|---|---|---|
LPTX | Leap Therapeutics | 26.15% | 41.9M |
CRIS | Curis | -1.35% | 30.2M |
COEP | Coeptis Therapeutics | 0% | 33.5M |
PHXM | PHAXIAM Therapeutics | -6.4% | 28.9M |
ALGS | Aligos Therapeutics | -4.01% | 33.4M |
You can purchase shares of Leap Therapeutics (NASDAQ: LPTX) through any online brokerage.
Other companies in Leap Therapeutics’s space includes: Curis (NASDAQ:CRIS), Coeptis Therapeutics (NASDAQ:COEP), PHAXIAM Therapeutics (NASDAQ:PHXM), Aligos Therapeutics (NASDAQ:ALGS) and NuCana (NASDAQ:NCNA).
The latest price target for Leap Therapeutics (NASDAQ: LPTX) was reported by Baird on Tuesday, August 15, 2023. The analyst firm set a price target for 20.00 expecting LPTX to rise to within 12 months (a possible 1119.51% upside). 12 analyst firms have reported ratings in the last year.
The stock price for Leap Therapeutics (NASDAQ: LPTX) is $1.64 last updated October 3, 2023 at 11:40 PM UTC.
There is no dividend information for Leap Therapeutics.
Leap Therapeutics’s Q3 earnings are confirmed for Monday, November 13, 2023.
There is no upcoming split for Leap Therapeutics.
Leap Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.